Our previous direct ex vivo analyses in PBMCs from patients with COVID-19, and also pre-pandemic PBMCs, tonsils, lungs, and spleens, assessing CD8+ T cells directed at four SARS-CoV-2 epitopes (B7/N105, B7/N257, A2/S269, and A24/S1208), demonstrate that B7/N105+CD8+ T cells were immunodominant by up to 38-fold in patients with COVID-19 and pre-pandemic samples, comparing with three subdominant SARS-CoV-2-specific CD8+ T cell populations. This evidence concerns the gene CD8A and COVID-19.